Alkermes Plc (NASDAQ:ALKS)

58.60
Delayed Data
As of Feb 23
 +2.05 / +3.63%
Today’s Change
46.43
Today|||52-Week Range
71.22
+7.07%
Year-to-Date
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
Feb 15 / Zacks.com - Paid Partner Content
Why Earnings Season Could Be Great for Alkermes (ALKS)
Feb 12 / Zacks.com - Paid Partner Content
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
Feb 14 / Zacks.com - Paid Partner Content
Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?
Feb 12 / Zacks.com - Paid Partner Content
Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
Feb 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close56.55
Today’s open56.67
Day’s range56.57 - 58.88
Volume937,105
Average volume (3 months)1,048,398
Market cap$9.2B
Data as of 4:00pm ET, 02/23/2018

Growth & Valuation

Earnings growth (last year)+25.36%
Earnings growth (this year)-90.40%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+21.15%
P/E ratioNM
Price/Sales9.29
Price/Book7.50

Competitors

 Today’s
change
Today’s
% change
ALNYAlnylam Pharmaceutic...+1.56+1.30%
SGENSeattle Genetics Inc+1.57+2.92%
TSROTESARO Inc-0.15-0.25%
IONSIonis Pharmaceutical...+1.15+2.31%
Data as of 4:00pm ET, 02/23/2018

Financials

Next reporting dateMay 3, 2018
EPS forecast (this quarter)$0.24
Annual revenue (last year)$903.4M
Annual profit (last year)-$157.9M
Net profit margin-17.48%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
Senior Vice President-
Operations
Declan O'Connor
Corporate headquarters
Dublin, Dublin

Forecasts